secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-02-19T23:59:59+00:00
Accession:  0001636282-26-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics reports Q4 2025 net loss of $62.5M; cash $756.5M; Phase 2 readouts expected Q2/Q4 2026
--------------------------------------------------------------------------------

- Q4 2025 net loss $62.5M (vs $56.3M Q4 2024); R&D expense $44.6M (vs $50.5M).
- Cash, cash equivalents, and marketable securities $756.5M at Dec 31, 2025; raised $316.2M gross in Oct 2025 public offering.
- On track for 6 proof-of-concept readouts in 2026: SKYLINE Part A (IBD) data expected Q2 2026; SKYWAY trial (RA, PsA, axSpA) data expected Q4 2026.
- Appointed Kate Tansey Chevlen as Chief Commercial Officer.
- Expected cash runway into second half of 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/0001636282-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000022/syre-20260219.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer